Sanjiu Medical Kicks Off Industrial Park Operation
This article was originally published in PharmAsia News
Executive Summary
With the backing of main shareholder China Resources Enterprise, restructured Sanjiu Medical & Pharmaceutical has finished constructing its industrial park and begun operations. The 300-million-yuan phase one project, located in the city's Guanlan High Tech Area, occupies 110,000 square meters. Sanjiu will acquire another 70,000 square meters for phase two, earmarked for related pharmaceutical production and auxiliary facilities. According to CR Enterprise, Sanjiu will focus on OTC brands as its core business, with TCM prescription and free-decocting TCM as fast-growth areas. The firm will reorganize its antibiotics and generics business to enter the tier-three end-user market. The latest event marks a key milestone for CR Enterprise, which will base its pharmaceutical headquarters in Shenzhen to further boost the business. (Click here for more - Chinese Language)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.